* Industry diversification based on Moody's industry classification. Measured as the fair value of investments for each category against the total fair value of all investments. Totals may not sum due to rounding.

A balanced portfolio built on the cornerstones of diversification and selectivity
Anchored in senior secured loans, NCDL has built a scaled and diversified portfolio by industry, investment type and portfolio company. Selectivity, diversification and rigorous underwriting are key to our investment philosophy, enabling strong credit performance since inception.
Portfolio holdings
Top ten positions
Represents the top ten positions in NCDL based on Fair Value as of March 31, 2025
Company | Fair value ($ in thousands) | Industry | Asset Types | Pricing1 |
---|---|---|---|---|
Quartz Holding Company (Quickbase) | 6,799,595 | High Tech Industries | First Lien Debt | S + 3.50% |
Solve Group Holdings, L.P. (Solve Industrial) | 153,447 | High Tech Industries | Equity Investment | |
Solve Industrial Motion Group LLC | 2,063,398 | High Tech Industries | Subordinated Debt (Delayed Draw) | 10.00% (Cash) 2.00% (PIK) |
Ridge Trail US Bidco, Inc. (Options IT) | 20,528 | High Tech Industries | Revolving Loan | S + 4.50% |
Revalize Inc. (f/k/a AQ Holdco Inc.) | 709,402 | High Tech Industries | First Lien Debt (Delayed Draw) | S + 5.75% |
Revalize Inc. (f/k/a AQ Holdco Inc.) | 1,028,364 | High Tech Industries | First Lien Debt (Delayed Draw) | S + 5.75% |
Revalize Inc. (f/k/a AQ Holdco Inc.) | 228,020 | High Tech Industries | First Lien Debt (Delayed Draw) | S + 5.75% |
Ridge Trail US Bidco, Inc. (Options IT) | 676,972 | High Tech Industries | First Lien Debt | S + 4.50% |
Ridge Trail US Bidco, Inc. (Options IT) | (2,197) | High Tech Industries | First Lien Debt (Delayed Draw) | S + 4.50% |
GHR Healthcare, LLC | 6,097,883 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
GHR Healthcare, LLC | 1,907,407 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.25% |
GHR Healthcare, LLC | (68,324) | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.25% |
HMA Equity, LP (Health Management Associates) | 445,893 | Healthcare & Pharmaceuticals | Equity Investment | |
FH DMI Buyer, Inc. | 1,968,728 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.00% |
GHR Healthcare, LLC | (22,765) | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.25% |
FH DMI Buyer, Inc. | 194,325 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.00% |
Genesee Scientific LLC | 5,112,970 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.75% |
Genesee Scientific LLC | 1,338,576 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.75% |
Heartland Veterinary Partners LLC | 3,694,344 | Healthcare & Pharmaceuticals | Subordinated Debt (Delayed Draw) | 7.50% (Cash) 7.00% (PIK) |
Eyesouth Eye Care Holdco LLC | 2,377,061 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.50% |
Heartland Veterinary Partners LLC | 10,176,414 | Healthcare & Pharmaceuticals | Subordinated Debt (Delayed Draw) | 7.50% (Cash) 7.00% (PIK) |
Heartland Veterinary Partners LLC | 2,035,283 | Healthcare & Pharmaceuticals | Subordinated Debt | 7.50% (Cash) 7.00% (PIK) |
HemaSource, Inc. | 5,277,484 | Healthcare & Pharmaceuticals | Subordinated Debt | 8.50% (Cash) 5.00% (PIK) |
Healthspan Buyer, LLC (Thorne HealthTech) | 10,469,533 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
Health Management Associates, Inc. | 1,063,441 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 6.25% |
GHR Healthcare, LLC | 7,745,902 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
GHR Healthcare, LLC | 3,601,529 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
Health Management Associates, Inc. | 8,204,593 | Healthcare & Pharmaceuticals | First Lien Debt | S + 6.25% |
GHR Healthcare, LLC | 4,747,226 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
Bridges Consumer Healthcare Intermediate LLC | 2,180,642 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.25% |
1. The majority of the investments bear interest at rates that may be determined by reference to Secured Overnight Financing Rate ("SOFR" or "S"), which reset monthly or quarterly. For each such investment, the Company has provided the spread over SOFR and the current contractual interest rate in effect at March 31, 2025. As of March 31, 2025, rates for 1M S, 3M S, 6M S, 12M S ("SOFR") are 4.32%, 4.29%, 4.19%, and 4.01% respectively. Certain investments are subject to a SOFR floor or may utilize an alternative reference rate such as U.S. Prime Rate (“P”). For fixed rate loans, a spread above a reference rate is not applicable.